BEAM-302 — first in vivo correction of a disease-causing point mutation in humans
官方名称: A Study of BEAM-302 in Patients With Alpha-1 Antitrypsin Deficiency
RecruitingPhase I/IINCT06389474
Clinical researchBeing tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.
本试验正在测试什么
This trial did the thing most people picture when they hear 'gene editing': it corrected the actual mutation, inside patients' own livers, after a single infusion. A 60 mg dose raised the protective protein above the level associated with lung protection in everyone who received it, and the trial moved into its pivotal stage in 2026.
A Phase 1/2 study, now with a global pivotal cohort, of BEAM-302, an in vivo base editor correcting the SERPINA1 PiZ mutation. It produced the first clinical demonstration of correcting a disease-causing point mutation in vivo in humans; a single 60 mg dose raised total alpha-1 antitrypsin above the protective threshold in all patients dosed at that level, and 60 mg was selected for pivotal development.